Arcus Biosciences, Inc. (NYSE: RCUS) Stock Competitors & Peer Comparison
See RCUS's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for RCUS and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| RCUS | $30.12 | -0.73% | 3.8B | -7.73 | -$3.90 | N/A |
| VRTX | $547.59 | -0.08% | 139B | 28.78 | $19.03 | N/A |
| REGN | $828.50 | -0.66% | 85.4B | 18.16 | $45.63 | +0.45% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $1,011.11 | -2.76% | 62.9B | 91.26 | $11.08 | N/A |
| MRNA | $138.89 | -4.30% | 55.1B | -17.04 | -$8.15 | N/A |
| RVMDW | $12.03 | +1.95% | 47.7B | -1.69 | -$7.21 | N/A |
| RVMD | $211.58 | +1.01% | 45B | -23.99 | -$8.82 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ONC | $371.98 | -0.66% | 39.7B | 65.49 | $5.68 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
RCUS vs VRTX Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, VRTX has a market cap of 139B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while VRTX trades at $547.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas VRTX's P/E ratio is 28.78. In terms of profitability, RCUS's ROE is -0.88%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, RCUS is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
RCUS vs REGN Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, REGN has a market cap of 85.4B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while REGN trades at $828.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas REGN's P/E ratio is 18.16. In terms of profitability, RCUS's ROE is -0.88%, compared to REGN's ROE of +0.14%. Regarding short-term risk, RCUS is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
RCUS vs VRNA Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas VRNA's P/E ratio is -102.80. In terms of profitability, RCUS's ROE is -0.88%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, RCUS is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
RCUS vs ARGX Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, ARGX has a market cap of 62.9B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while ARGX trades at $1,011.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas ARGX's P/E ratio is 91.26. In terms of profitability, RCUS's ROE is -0.88%, compared to ARGX's ROE of +0.32%. Regarding short-term risk, RCUS is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check ARGX's competition here
Moderna, Inc. (NASDAQ: MRNA)
RCUS vs MRNA Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, MRNA has a market cap of 55.1B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while MRNA trades at $138.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas MRNA's P/E ratio is -17.04. In terms of profitability, RCUS's ROE is -0.88%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, RCUS is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for RCUS.Check MRNA's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
RCUS vs RVMDW Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, RVMDW has a market cap of 47.7B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while RVMDW trades at $12.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas RVMDW's P/E ratio is -1.69. In terms of profitability, RCUS's ROE is -0.88%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, RCUS is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for RCUS.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
RCUS vs RVMD Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, RVMD has a market cap of 45B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while RVMD trades at $211.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas RVMD's P/E ratio is -23.99. In terms of profitability, RCUS's ROE is -0.88%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, RCUS is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check RVMD's competition here
Seagen Inc. (NASDAQ: SGEN)
RCUS vs SGEN Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas SGEN's P/E ratio is -57.19. In terms of profitability, RCUS's ROE is -0.88%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, RCUS is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check SGEN's competition here
BeOne Medicines AG (NASDAQ: ONC)
RCUS vs ONC Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, ONC has a market cap of 39.7B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while ONC trades at $371.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas ONC's P/E ratio is 65.49. In terms of profitability, RCUS's ROE is -0.88%, compared to ONC's ROE of +0.14%. Regarding short-term risk, RCUS is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
RCUS vs ALNY Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, ALNY has a market cap of 31.6B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while ALNY trades at $236.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas ALNY's P/E ratio is 42.52. In terms of profitability, RCUS's ROE is -0.88%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, RCUS is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check ALNY's competition here
BioNTech SE (NASDAQ: BNTX)
RCUS vs BNTX Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, BNTX has a market cap of 28.3B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while BNTX trades at $112.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas BNTX's P/E ratio is -14.63. In terms of profitability, RCUS's ROE is -0.88%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, RCUS is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check BNTX's competition here
Insmed Incorporated (NASDAQ: INSM)
RCUS vs INSM Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, INSM has a market cap of 26.9B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while INSM trades at $123.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas INSM's P/E ratio is -30.17. In terms of profitability, RCUS's ROE is -0.88%, compared to INSM's ROE of -1.11%. Regarding short-term risk, RCUS is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check INSM's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
RCUS vs ROIV Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, ROIV has a market cap of 26.3B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while ROIV trades at $36.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas ROIV's P/E ratio is -34.59. In terms of profitability, RCUS's ROE is -0.88%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, RCUS is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check ROIV's competition here
Incyte Corporation (NASDAQ: INCY)
RCUS vs INCY Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, INCY has a market cap of 25.9B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while INCY trades at $127.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas INCY's P/E ratio is 17.20. In terms of profitability, RCUS's ROE is -0.88%, compared to INCY's ROE of +0.30%. Regarding short-term risk, RCUS is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check INCY's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
RCUS vs UTHR Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, UTHR has a market cap of 21.8B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while UTHR trades at $512.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas UTHR's P/E ratio is 18.36. In terms of profitability, RCUS's ROE is -0.88%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, RCUS is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check UTHR's competition here
Genmab A/S (NASDAQ: GMAB)
RCUS vs GMAB Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, GMAB has a market cap of 20.3B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while GMAB trades at $33.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas GMAB's P/E ratio is 24.88. In terms of profitability, RCUS's ROE is -0.88%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, RCUS is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check GMAB's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
RCUS vs BGNE Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas BGNE's P/E ratio is -22.55. In terms of profitability, RCUS's ROE is -0.88%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, RCUS is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
RCUS vs DNA-WT Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, RCUS's ROE is -0.88%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, RCUS is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for RCUS.Check DNA-WT's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
RCUS vs JAZZ Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, JAZZ has a market cap of 16B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while JAZZ trades at $254.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas JAZZ's P/E ratio is 9.49. In terms of profitability, RCUS's ROE is -0.88%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, RCUS is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check JAZZ's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
RCUS vs BBIO Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, BBIO has a market cap of 15.9B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while BBIO trades at $81.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas BBIO's P/E ratio is -21.68. In terms of profitability, RCUS's ROE is -0.88%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, RCUS is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check BBIO's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
RCUS vs ASND Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, ASND has a market cap of 15.6B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while ASND trades at $251.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas ASND's P/E ratio is -104.11. In terms of profitability, RCUS's ROE is -0.88%, compared to ASND's ROE of +1.90%. Regarding short-term risk, RCUS is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check ASND's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
RCUS vs NBIX Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, NBIX has a market cap of 15.4B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while NBIX trades at $153.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas NBIX's P/E ratio is 22.12. In terms of profitability, RCUS's ROE is -0.88%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, RCUS is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check NBIX's competition here
Exelixis, Inc. (NASDAQ: EXEL)
RCUS vs EXEL Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, EXEL has a market cap of 13.7B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while EXEL trades at $54.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas EXEL's P/E ratio is 15.59. In terms of profitability, RCUS's ROE is -0.88%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, RCUS is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check EXEL's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
RCUS vs HALO Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, HALO has a market cap of 12.9B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while HALO trades at $108.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas HALO's P/E ratio is 20.27. In terms of profitability, RCUS's ROE is -0.88%, compared to HALO's ROE of +1.81%. Regarding short-term risk, RCUS is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check HALO's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
RCUS vs KRTX Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas KRTX's P/E ratio is -28.09. In terms of profitability, RCUS's ROE is -0.88%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, RCUS is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check KRTX's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
RCUS vs BMRN Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, BMRN has a market cap of 12.6B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while BMRN trades at $65.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas BMRN's P/E ratio is 31.28. In terms of profitability, RCUS's ROE is -0.88%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, RCUS is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check BMRN's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
RCUS vs ARWR Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, ARWR has a market cap of 12.2B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while ARWR trades at $86.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas ARWR's P/E ratio is -38.55. In terms of profitability, RCUS's ROE is -0.88%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, RCUS is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check ARWR's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
RCUS vs MDGL Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, MDGL has a market cap of 11.8B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while MDGL trades at $511.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas MDGL's P/E ratio is -40.00. In terms of profitability, RCUS's ROE is -0.88%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, RCUS is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check MDGL's competition here
Bio-Techne Corporation (NASDAQ: TECH)
RCUS vs TECH Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while TECH trades at $72.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas TECH's P/E ratio is 37.31. In terms of profitability, RCUS's ROE is -0.88%, compared to TECH's ROE of +0.09%. Regarding short-term risk, RCUS is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
RCUS vs RNAM Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas RNAM's P/E ratio is -17.39. In terms of profitability, RCUS's ROE is -0.88%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, RCUS is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check RNAM's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
RCUS vs AXSM Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, AXSM has a market cap of 10.6B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while AXSM trades at $205.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas AXSM's P/E ratio is -53.63. In terms of profitability, RCUS's ROE is -0.88%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, RCUS is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check AXSM's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
RCUS vs IONS Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, IONS has a market cap of 10.3B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while IONS trades at $62.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas IONS's P/E ratio is -36.07. In terms of profitability, RCUS's ROE is -0.88%, compared to IONS's ROE of -1.11%. Regarding short-term risk, RCUS is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check IONS's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
RCUS vs PRAX Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, PRAX has a market cap of 10.3B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while PRAX trades at $368.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas PRAX's P/E ratio is -28.46. In terms of profitability, RCUS's ROE is -0.88%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, RCUS is more volatile compared to PRAX. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check PRAX's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
RCUS vs SMMT Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, SMMT has a market cap of 10.2B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while SMMT trades at $12.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas SMMT's P/E ratio is -11.37. In terms of profitability, RCUS's ROE is -0.88%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, RCUS is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for RCUS.Check SMMT's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
RCUS vs KRYS Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, KRYS has a market cap of 10.1B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while KRYS trades at $341.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas KRYS's P/E ratio is 42.82. In terms of profitability, RCUS's ROE is -0.88%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, RCUS is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check KRYS's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
RCUS vs KYMR Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, KYMR has a market cap of 10B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while KYMR trades at $121.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas KYMR's P/E ratio is -37.83. In terms of profitability, RCUS's ROE is -0.88%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, RCUS is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check KYMR's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
RCUS vs PTGX Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, PTGX has a market cap of 10B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while PTGX trades at $154.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas PTGX's P/E ratio is 150.21. In terms of profitability, RCUS's ROE is -0.88%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, RCUS is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for RCUS.Check PTGX's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
RCUS vs CYTK Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, CYTK has a market cap of 9.6B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while CYTK trades at $77.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas CYTK's P/E ratio is -10.68. In terms of profitability, RCUS's ROE is -0.88%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, RCUS is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check CYTK's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
RCUS vs RXDX Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas RXDX's P/E ratio is -56.47. In terms of profitability, RCUS's ROE is -0.88%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, RCUS is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check RXDX's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
RCUS vs SYRE Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, SYRE has a market cap of 9.3B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while SYRE trades at $106.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas SYRE's P/E ratio is -54.69. In terms of profitability, RCUS's ROE is -0.88%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, RCUS is more volatile compared to SYRE. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check SYRE's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
RCUS vs NUVL Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas NUVL's P/E ratio is -21.79. In terms of profitability, RCUS's ROE is -0.88%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, RCUS is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check NUVL's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
RCUS vs CRNX Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while CRNX trades at $84.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas CRNX's P/E ratio is -16.82. In terms of profitability, RCUS's ROE is -0.88%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, RCUS is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check CRNX's competition here
Immunovant, Inc. (NASDAQ: IMVT)
RCUS vs IMVT Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, IMVT has a market cap of 8.9B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while IMVT trades at $43.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas IMVT's P/E ratio is -15.36. In terms of profitability, RCUS's ROE is -0.88%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, RCUS is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check IMVT's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
RCUS vs PCVX Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, PCVX has a market cap of 8.9B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while PCVX trades at $61.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas PCVX's P/E ratio is -8.11. In terms of profitability, RCUS's ROE is -0.88%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, RCUS is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check PCVX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
RCUS vs IMGN Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas IMGN's P/E ratio is -111.55. In terms of profitability, RCUS's ROE is -0.88%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, RCUS is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check IMGN's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
RCUS vs TGTX Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, TGTX has a market cap of 8.6B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while TGTX trades at $56.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas TGTX's P/E ratio is 20.29. In terms of profitability, RCUS's ROE is -0.88%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, RCUS is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for RCUS.Check TGTX's competition here
Abivax S.A. (NASDAQ: ABVX)
RCUS vs ABVX Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, ABVX has a market cap of 8.5B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while ABVX trades at $116.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas ABVX's P/E ratio is -60.88. In terms of profitability, RCUS's ROE is -0.88%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, RCUS is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check ABVX's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
RCUS vs BPMC Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas BPMC's P/E ratio is -51.58. In terms of profitability, RCUS's ROE is -0.88%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, RCUS is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
RCUS vs APGE Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while APGE trades at $134.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas APGE's P/E ratio is -31.13. In terms of profitability, RCUS's ROE is -0.88%, compared to APGE's ROE of -0.30%. Regarding short-term risk, RCUS is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check APGE's competition here
Alkermes plc (NASDAQ: ALKS)
RCUS vs ALKS Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, ALKS has a market cap of 8.2B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while ALKS trades at $48.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas ALKS's P/E ratio is 51.44. In terms of profitability, RCUS's ROE is -0.88%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, RCUS is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check ALKS's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
RCUS vs CERE Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas CERE's P/E ratio is -16.47. In terms of profitability, RCUS's ROE is -0.88%, compared to CERE's ROE of -0.72%. Regarding short-term risk, RCUS is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check CERE's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
RCUS vs IBRX Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, IBRX has a market cap of 7.9B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while IBRX trades at $7.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas IBRX's P/E ratio is -7.81. In terms of profitability, RCUS's ROE is -0.88%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, RCUS is more volatile compared to IBRX. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check IBRX's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
RCUS vs RYTM Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, RYTM has a market cap of 7.6B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while RYTM trades at $111.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas RYTM's P/E ratio is -35.83. In terms of profitability, RCUS's ROE is -0.88%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, RCUS is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check RYTM's competition here
Metsera, Inc. (NASDAQ: MTSR)
RCUS vs MTSR Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas MTSR's P/E ratio is -23.58. In terms of profitability, RCUS's ROE is -0.88%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, RCUS is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check MTSR's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
RCUS vs CAI Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, CAI has a market cap of 7.4B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while CAI trades at $26.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas CAI's P/E ratio is 73.42. In terms of profitability, RCUS's ROE is -0.88%, compared to CAI's ROE of +0.19%. Regarding short-term risk, RCUS is more volatile compared to CAI. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check CAI's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
RCUS vs SRRK Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, SRRK has a market cap of 7B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while SRRK trades at $58.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas SRRK's P/E ratio is -16.87. In terms of profitability, RCUS's ROE is -0.88%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, RCUS is more volatile compared to SRRK. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check SRRK's competition here
CG Oncology Inc. (NASDAQ: CGON)
RCUS vs CGON Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, CGON has a market cap of 6.9B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while CGON trades at $78.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas CGON's P/E ratio is -29.08. In terms of profitability, RCUS's ROE is -0.88%, compared to CGON's ROE of -0.25%. Regarding short-term risk, RCUS is more volatile compared to CGON. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check CGON's competition here
Merus N.V. (NASDAQ: MRUS)
RCUS vs MRUS Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas MRUS's P/E ratio is -17.05. In terms of profitability, RCUS's ROE is -0.88%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, RCUS is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check MRUS's competition here
Arcellx, Inc. (NASDAQ: ACLX)
RCUS vs ACLX Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas ACLX's P/E ratio is -28.27. In terms of profitability, RCUS's ROE is -0.88%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, RCUS is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check ACLX's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
RCUS vs RETA Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas RETA's P/E ratio is -66.29. In terms of profitability, RCUS's ROE is -0.88%, compared to RETA's ROE of +0.47%. Regarding short-term risk, RCUS is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check RETA's competition here
Belite Bio, Inc (NASDAQ: BLTE)
RCUS vs BLTE Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, BLTE has a market cap of 6.4B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while BLTE trades at $158.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas BLTE's P/E ratio is -84.96. In terms of profitability, RCUS's ROE is -0.88%, compared to BLTE's ROE of -0.21%. Regarding short-term risk, RCUS is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check BLTE's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
RCUS vs CNTA Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas CNTA's P/E ratio is -22.63. In terms of profitability, RCUS's ROE is -0.88%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, RCUS is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check CNTA's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
RCUS vs COGT Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, COGT has a market cap of 6.2B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while COGT trades at $36.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas COGT's P/E ratio is -17.17. In terms of profitability, RCUS's ROE is -0.88%, compared to COGT's ROE of -0.73%. Regarding short-term risk, RCUS is more volatile compared to COGT. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check COGT's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
RCUS vs ORKA Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, ORKA has a market cap of 6.2B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while ORKA trades at $102.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas ORKA's P/E ratio is -52.79. In terms of profitability, RCUS's ROE is -0.88%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, RCUS is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for RCUS.Check ORKA's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
RCUS vs DNTH Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, DNTH has a market cap of 6.2B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while DNTH trades at $110.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas DNTH's P/E ratio is -26.52. In terms of profitability, RCUS's ROE is -0.88%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, RCUS is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for RCUS.Check DNTH's competition here
Erasca, Inc. (NASDAQ: ERAS)
RCUS vs ERAS Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, ERAS has a market cap of 6.1B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while ERAS trades at $17.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas ERAS's P/E ratio is -18.92. In terms of profitability, RCUS's ROE is -0.88%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, RCUS is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for RCUS.Check ERAS's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
RCUS vs TVTX Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, TVTX has a market cap of 6.1B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while TVTX trades at $65.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas TVTX's P/E ratio is -144.93. In terms of profitability, RCUS's ROE is -0.88%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, RCUS is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check TVTX's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
RCUS vs PTCT Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, PTCT has a market cap of 5.9B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while PTCT trades at $71.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas PTCT's P/E ratio is -30.50. In terms of profitability, RCUS's ROE is -0.88%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, RCUS is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check PTCT's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
RCUS vs MIRM Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, MIRM has a market cap of 5.9B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while MIRM trades at $96.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas MIRM's P/E ratio is -6.65. In terms of profitability, RCUS's ROE is -0.88%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, RCUS is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check MIRM's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
RCUS vs XENE Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, XENE has a market cap of 5.9B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while XENE trades at $60.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas XENE's P/E ratio is -12.89. In terms of profitability, RCUS's ROE is -0.88%, compared to XENE's ROE of -0.44%. Regarding short-term risk, RCUS is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check XENE's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
RCUS vs DFTX Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, DFTX has a market cap of 5.7B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while DFTX trades at $43.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas DFTX's P/E ratio is N/A. In terms of profitability, RCUS's ROE is -0.88%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, RCUS is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for RCUS.Check DFTX's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
RCUS vs LGND Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, LGND has a market cap of 5.6B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while LGND trades at $280.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas LGND's P/E ratio is 30.76. In terms of profitability, RCUS's ROE is -0.88%, compared to LGND's ROE of +0.20%. Regarding short-term risk, RCUS is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check LGND's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
RCUS vs CDTX Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas CDTX's P/E ratio is -19.77. In terms of profitability, RCUS's ROE is -0.88%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, RCUS is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
RCUS vs ABCM Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, RCUS's ROE is -0.88%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, RCUS is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
RCUS vs ISEE Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas ISEE's P/E ratio is -22.44. In terms of profitability, RCUS's ROE is -0.88%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, RCUS is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check ISEE's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
RCUS vs CRSP Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, CRSP has a market cap of 5.5B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while CRSP trades at $57.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas CRSP's P/E ratio is -11.99. In terms of profitability, RCUS's ROE is -0.88%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, RCUS is more volatile compared to CRSP. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check CRSP's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
RCUS vs APLS Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas APLS's P/E ratio is 38.35. In terms of profitability, RCUS's ROE is -0.88%, compared to APLS's ROE of +0.40%. Regarding short-term risk, RCUS is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check APLS's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
RCUS vs ACAD Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, ACAD has a market cap of 5.1B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while ACAD trades at $29.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas ACAD's P/E ratio is 13.36. In terms of profitability, RCUS's ROE is -0.88%, compared to ACAD's ROE of +0.32%. Regarding short-term risk, RCUS is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check ACAD's competition here
Dyne Therapeutics, Inc. (NASDAQ: DYN)
RCUS vs DYN Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, DYN has a market cap of 4.9B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while DYN trades at $25.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas DYN's P/E ratio is -8.07. In terms of profitability, RCUS's ROE is -0.88%, compared to DYN's ROE of -0.64%. Regarding short-term risk, RCUS is more volatile compared to DYN. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check DYN's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
RCUS vs EWTX Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, EWTX has a market cap of 4.8B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while EWTX trades at $44.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas EWTX's P/E ratio is -24.17. In terms of profitability, RCUS's ROE is -0.88%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, RCUS is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for RCUS.Check EWTX's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
RCUS vs TERN Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas TERN's P/E ratio is -51.41. In terms of profitability, RCUS's ROE is -0.88%, compared to TERN's ROE of -0.20%. Regarding short-term risk, RCUS is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check TERN's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
RCUS vs FOLD Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas FOLD's P/E ratio is -161.00. In terms of profitability, RCUS's ROE is -0.88%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, RCUS is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
RCUS vs AKRO Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas AKRO's P/E ratio is -14.57. In terms of profitability, RCUS's ROE is -0.88%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, RCUS is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check AKRO's competition here
Parabilis Medicines, Inc. (NASDAQ: PBLS)
RCUS vs PBLS Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, PBLS has a market cap of 4.5B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while PBLS trades at $38.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas PBLS's P/E ratio is -43.67. In terms of profitability, RCUS's ROE is -0.88%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, RCUS is less volatile compared to PBLS. This indicates lower risk in terms of short-term price fluctuations for RCUS.Check PBLS's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
RCUS vs ALPN Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas ALPN's P/E ratio is -101.52. In terms of profitability, RCUS's ROE is -0.88%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, RCUS is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check ALPN's competition here
Celcuity Inc. (NASDAQ: CELC)
RCUS vs CELC Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, CELC has a market cap of 4.4B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while CELC trades at $90.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas CELC's P/E ratio is -21.11. In terms of profitability, RCUS's ROE is -0.88%, compared to CELC's ROE of -3.51%. Regarding short-term risk, RCUS is more volatile compared to CELC. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check CELC's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
RCUS vs ELVN Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, ELVN has a market cap of 4.4B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while ELVN trades at $61.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas ELVN's P/E ratio is -36.62. In terms of profitability, RCUS's ROE is -0.88%, compared to ELVN's ROE of -0.19%. Regarding short-term risk, RCUS is more volatile compared to ELVN. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check ELVN's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
RCUS vs RLAY Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, RLAY has a market cap of 4.3B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while RLAY trades at $19.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas RLAY's P/E ratio is -12.59. In terms of profitability, RCUS's ROE is -0.88%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, RCUS is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for RCUS.Check RLAY's competition here
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)
RCUS vs AMLX Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, AMLX has a market cap of 4.2B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while AMLX trades at $38.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas AMLX's P/E ratio is -25.43. In terms of profitability, RCUS's ROE is -0.88%, compared to AMLX's ROE of -0.53%. Regarding short-term risk, RCUS is more volatile compared to AMLX. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check AMLX's competition here
Opthea Limited (NASDAQ: OPT)
RCUS vs OPT Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas OPT's P/E ratio is -1.52. In terms of profitability, RCUS's ROE is -0.88%, compared to OPT's ROE of +1.18%. Regarding short-term risk, RCUS is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
RCUS vs PRTC Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas PRTC's P/E ratio is -3.78. In terms of profitability, RCUS's ROE is -0.88%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, RCUS is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check PRTC's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
RCUS vs MRTX Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas MRTX's P/E ratio is -4.82. In terms of profitability, RCUS's ROE is -0.88%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, RCUS is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check MRTX's competition here
Veradermics, Incorporated (NYSE: MANE)
RCUS vs MANE Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, MANE has a market cap of 4.1B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while MANE trades at $98.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas MANE's P/E ratio is -31.31. In terms of profitability, RCUS's ROE is -0.88%, compared to MANE's ROE of -0.29%. Regarding short-term risk, RCUS is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for RCUS.Check MANE's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
RCUS vs ADPT Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, ADPT has a market cap of 4.1B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while ADPT trades at $25.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas ADPT's P/E ratio is -62.32. In terms of profitability, RCUS's ROE is -0.88%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, RCUS is more volatile compared to ADPT. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check ADPT's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
RCUS vs TNGX Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, TNGX has a market cap of 4B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while TNGX trades at $24.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas TNGX's P/E ratio is -29.53. In terms of profitability, RCUS's ROE is -0.88%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, RCUS is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for RCUS.Check TNGX's competition here
Telix Pharmaceuticals Limited (NASDAQ: TLX)
RCUS vs TLX Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, TLX has a market cap of 4B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while TLX trades at $11.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas TLX's P/E ratio is 121.92. In terms of profitability, RCUS's ROE is -0.88%, compared to TLX's ROE of +0.07%. Regarding short-term risk, RCUS is more volatile compared to TLX. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check TLX's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
RCUS vs VKTX Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, VKTX has a market cap of 3.9B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while VKTX trades at $33.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas VKTX's P/E ratio is -7.13. In terms of profitability, RCUS's ROE is -0.88%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, RCUS is more volatile compared to VKTX. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check VKTX's competition here
Legend Biotech Corporation (NASDAQ: LEGN)
RCUS vs LEGN Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, LEGN has a market cap of 3.9B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while LEGN trades at $20.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas LEGN's P/E ratio is -30.79. In terms of profitability, RCUS's ROE is -0.88%, compared to LEGN's ROE of -0.09%. Regarding short-term risk, RCUS is less volatile compared to LEGN. This indicates lower risk in terms of short-term price fluctuations for RCUS.Check LEGN's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
RCUS vs CPRX Comparison August 2026
Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCUS stands at 3.8B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, RCUS is priced at $30.12 on the NYSE, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCUS currently has a P/E ratio of -7.73, whereas CPRX's P/E ratio is 12.30. In terms of profitability, RCUS's ROE is -0.88%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, RCUS is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check CPRX's competition here